Cell & Gene Therapy - Considering The Patient Pathway : IC Fireside Chats - Episode 2
In this episode, Omar Ali (Head of Payers, Verpora) and Adam Buckler (VP Innovative Contracting, Verpora) explore how Novartis structured its Zolgensma contracts to overcome market-specific barriers in the US, and LATAM (Brazil). From outcome-based agreements and staged payments to service-based discounts supporting diagnosis infrastructure, this discussion reveals the real-world contracting strategies shaping access to gene therapies globally.
This is the first of a two-part discussion—join us next week as we continue the conversation, exploring buyer’s remorse in gene therapy and what happens when outcomes don’t meet expectations.
Disclaimer: This presentation is for educational and informational purposes only, and is not intended as legal or policy advice. This presentation is based on non-confidential intelligence. Views expressed by the speakers are personal opinions and should not be attributed to anyone else. No part of this presentation may be reproduced for commercial purposes without the express permission of Verpora.
Never miss an episode
Receive a single email each week with a direct link to the latest IC Fireside Chat— no spam, just the latest episode, straight to your inbox.
Watch Next
